Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
Anything relating to the treatment and therapy available for CML
Post count:
2 856Thread count:
415Machine name:
treating_cmlYou are here
Treating CML
Overview CML 1st line, 2nd line, managing resistance- Michael Mauro
Treatment-free remission, stop trials, predictors for stopping treatment- Andreas Hochhaus
The patient perspective on treatment-free remission, including support needs- Pat Elliott
Panel discussion: The psychology of stopping treatment
Beyond TKIs - addressing different pathways (Arnon Nagler)
"Do we all do it in the same way?" EBMT documentary
DASISION
A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML
A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for CML in chronic phase
BCR-ABL1 mutations are a common, well-characterized mechanism of resistance to imatinib as first-line treatment of chronic myeloid leukemia in chronic phase (CML-CP). Less is known about mutation development during first-line treatment with dasatinib and nilotinib, despite increased use because of higher response rates compared with imatinib.
How to ensure you have an optimal response to TKI therapy
Armed with all this information, how can you help your body make the most optimal response possible to your TKI therapies?
Armed with all this information, how can you help your body make the most optimal response possible to your TKI therapies?